GeoVax Labs to Present at Two Major Investor Conferences in September

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company at the forefront of developing innovative immunotherapies and vaccines, has announced its participation in two major investor conferences this September. These events provide a platform for GeoVax to update the investment community on its latest advancements in the fight against cancers and infectious diseases.

David Dodd, the Chairman and CEO of GeoVax, will lead the company's presentations at both the H.C. Wainwright 26th Annual Global Investment Conference and the Emerging Growth Conference. These appearances come at a crucial time for the company, which is making significant strides in its clinical programs, particularly in COVID-19 vaccine development and cancer therapies.

At the H.C. Wainwright conference, scheduled for September 9, 2024, at 7:00 a.m. ET in New York City, Dodd will provide a corporate update. This in-person event offers a valuable opportunity for direct engagement with investors and industry professionals. Interested parties can access the presentation via a webcast link.

Later in the month, on September 25, 2024, at 2:55 p.m. ET, GeoVax will participate in the virtual Emerging Growth Conference. This online format allows for broader accessibility, enabling a wider audience to gain insights into GeoVax's latest developments. The presentation will be available through a dedicated webcast link.

These presentations come at a pivotal time for GeoVax, as the company advances its lead clinical program, GEO-CM04S1, a next-generation COVID-19 vaccine. The company recently secured a BARDA-funded contract for a 10,000-participant Phase 2b clinical trial, comparing GEO-CM04S1's efficacy against an approved COVID-19 vaccine. This development marks a significant milestone in GeoVax's efforts to address the ongoing global health challenge posed by COVID-19.

In addition to its COVID-19 vaccine work, GeoVax is making progress in oncology. The company is currently evaluating Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. This diversification into cancer treatment showcases GeoVax's commitment to addressing multiple critical areas of medical need.

GeoVax's participation in these investor conferences is not just an opportunity for the company to showcase its achievements but also a chance for investors and industry observers to gain valuable insights into the future of vaccine and immunotherapy development. As the biotechnology sector continues to play a crucial role in global health solutions, companies like GeoVax are at the forefront of innovation, potentially shaping the future of disease prevention and treatment.

The company's strong intellectual property portfolio and experienced leadership team further underscore its potential impact in the biotechnology field. With worldwide rights to its technologies and products, GeoVax is well-positioned to continue its trajectory of innovation and potential market disruption.

As GeoVax prepares to share its latest developments at these September conferences, the biotechnology and investment communities will be watching closely. The outcomes of these presentations could have far-reaching implications for the company's future funding, partnerships, and overall trajectory in the competitive landscape of vaccine and immunotherapy development.